Radium-223 chloride, a first-in-class alpha-pharmaceutical with a benign safety profile for patients with castration-resistant prostate cancer (CRPC) and bone metastases: Combined analysis of phase I and II clinical trials.

Sten Nilsson,Chris Parker,I. Haugen,A. Lokna,Anne-Kirsti Aksnes,B. Bolstad,G. O'Bryan-Tear,Øyvind S. Bruland

Radium-223 chloride, a first-in-class alpha-pharmaceutical with a benign safety profile for patients with castration-resistant prostate cancer (CRPC) and bone metastases: Combined analysis of phase I and II clinical trials.

2010

Sten Nilsson
Chris Parker
I. Haugen
A. Lokna
Anne-Kirsti Aksnes
B. Bolstad
G. O'Bryan-Tear
Øyvind S. Bruland

4678 Background: Radium-223 chloride (Alpharadin) is a first-in-class alpha- pharmaceutical which has a potent and highly targeted antitumor effect on bone metastases. Efficacy, safety and tolerabi...

Keywords:

Pathology
Clinical trial
Prostate cancer
Castration
Alpha (ethology)
Oncology
Medicine
Radium-223 chloride
Internal medicine
safety profile
castration resistant

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations